Intermittent Versus Continuous Infusion Meropenem in Cystic Fibrosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2013-12-31

Study Completion Date

2015-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the incidence of nausea and vomiting following short intermittent versus prolonged intermittent infusion of meropenem.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Resident Surveillance of Pediatric Patient Developmental Status at the Two Month Preventive Care Visit

NCT00465361

Growth & Development Child Development Internship and Residency +2 more

COMPLETED NA

Two Anesthetic Techniques in Magnetic Resonance Imaging (MRI)

NCT00894751

Magnetic Resonance Imaging Anesthesia

TERMINATED PHASE1

Normal Liver Stiffness by MR Elastography

NCT03235414

Liver Diseases

COMPLETED NA

Assessment of an App Based on Artificial Intelligence for Purulent AOM Diagnosis in a Pediatric Department

NCT04752891

Otitis Media, Suppurative

COMPLETED NA

Magnetic Resonance Elastography in Infants

NCT02201472

Liver Disease

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. To assess the number of episodes of emesis following both short and prolonged intermittent infusion of meropenem.
2. To assess the number of episodes of emesis corresponding to the peak serum concentration of meropenem.
3. To assess the number of episodes of emesis corresponding to the area under the meropenem serum concentration time curve.
4. To assess reported nausea, measured through administered dosages of anti-nausea medication, following both short and prolonged intermittent infusion of meropenem.
5. To assess reported nausea, measured through administered doses of anti-nausea medication, corresponding to peak concentrations of meropenem.
6. To assess reported nausea, measured through administered dosages of anti-nausea medication, corresponding to the area under the serum concentration time curve
7. To assess reported nausea, measured through patient-reported nausea measured using pictorial scales of severity of nausea in pediatric patients, following both short and prolonged intermittent infusion of meropenem.
8. To assess reported nausea, measured through patient-reported nausea measured using pictorial scales of severity corresponding to the peak serum concentrations of meropenem.
9. To assess reported nausea, measured through patient-reported nausea measured using pictorial scales of severity corresponding to the area under the meropenem serum concentration time curve.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cystic Fibrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CROSSOVER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Short infusion meropenem

Meropenem 20 mg/ml IV will be administered at a dose of 40 mg/kg (maximum 2,000 mg) every eight hours for 12 doses and will be infused over a 30 minute period. An equal volume of normal saline will be infused at the same time over four hours.

No interventions assigned to this group

Prolonged infusion meropenem

Meropenem 20 mg/ml IV will be administered at a dose of 40 mg/kg (maximum 2,000 mg) every eight hours for 12 doses and will be infused over a four hour period. An equal volume of normal saline will be infused at the same time over 30 minutes.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Be an admitted patient at Dayton Children's Hospital.
2. Between 7 and 21 years of age.
3. Have a documented CF diagnosis with one or more of the following clinical features:

1. Sweat chloride \> 60 mEq/liter as determined by quantitative pilocarpine iontophoresis test (QPIT).
2. Two mutations (well characterized) in the cystic fibrosis transmembrane conductive regulator (CTFR) gene.
3. Abnormal nasal potential difference.
4. Based on Hankinson/NHanes III criteria, are able to elicit an FEV1 \> 25% but with \< 95% predicted value when admitted.
5. Sputum or throat swab specimen positive for P. aeruginosa and have a history of at least one additional sputum culture positive for P. aeruginosa within the last 12 months.
6. Are able to perform an acceptable spirometry session (defined as 3 acceptable or usable efforts per ATS/ERS criteria upon admission).
7. Have not smoked tobacco within 28 days prior to Visit 1 and agree not to smoke for the duration of the study.
8. Are able to and have given written informed consent (if they are adults) or assent in combination with consent of their legal representative(s) (if they are minors) in a manner approved by the Institutional Review Board.
9. Patient is experiencing symptoms of CF exacerbation of CF: with any 4 of the following 12 signs or symptoms:

* Change in sputum;
* New or increased hemoptysis;
* Increased cough;
* Increased dyspnea;
* Malaise, fatigue or lethargy;
* Temperature above 38°C;
* Anorexia or weight loss;
* Sinus pain or tenderness;
* Change in sinus discharge;
* Change in physical examination of the chest;
* Decrease in pulmonary function by 10 percent or more from a previously recorded value;
* Radiographic changes indicative of pulmonary infection.

Exclusion Criteria

1. History of hypersensitivity or intolerance to meropenem.
2. History of hypersensitivity or intolerance to granisetron.
3. Are pregnant, breastfeeding, or unwilling to practice a highly effective method of birth control or abstinence during participation in the study.

Minimum Eligible Age

7 Years

Maximum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No